secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001493152-26-021112
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ernexa Therapeutics effects 1-for-25 reverse stock split, effective May 4, 2026
-------------------------------------------------------------------------------

- Reverse stock split at 1-for-25 ratio; trading on split-adjusted basis began at market open on May 4, 2026.
- Certificate of Amendment filed with Delaware Secretary of State on May 1, 2026.
- New CUSIP number for common stock post-split: 114082407.
- Common stock (ERNA) and warrants (ERNAW) trade on Nasdaq under split-adjusted terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315226021112/0001493152-26-021112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315226021112/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-021112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer